<SEC-DOCUMENT>0000950170-25-076523.txt : 20250522
<SEC-HEADER>0000950170-25-076523.hdr.sgml : 20250522
<ACCEPTANCE-DATETIME>20250522182725
ACCESSION NUMBER:		0000950170-25-076523
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250521
FILED AS OF DATE:		20250522
DATE AS OF CHANGE:		20250522

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			QUAY STEVEN C
		CENTRAL INDEX KEY:			0001008227
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35610
		FILM NUMBER:		25978626

	MAIL ADDRESS:	
		STREET 1:		22026 20TH AVENUE S E
		STREET 2:		SUITE 102
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98021

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATOSSA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001488039
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				264753208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		10202 5TH AVENUE NE
		STREET 2:		SUITE 200
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98125
		BUSINESS PHONE:		206.588.0256

	MAIL ADDRESS:	
		STREET 1:		10202 5TH AVENUE NE
		STREET 2:		SUITE 200
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98125

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATOSSA GENETICS INC
		DATE OF NAME CHANGE:	20100325
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-05-21</periodOfReport>

    <issuer>
        <issuerCik>0001488039</issuerCik>
        <issuerName>ATOSSA THERAPEUTICS, INC.</issuerName>
        <issuerTradingSymbol>ATOS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001008227</rptOwnerCik>
            <rptOwnerName>QUAY STEVEN C</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ATOSSA THERAPEUTICS, INC.,</rptOwnerStreet1>
            <rptOwnerStreet2>10202 5TH AVE NE, SUITE 200</rptOwnerStreet2>
            <rptOwnerCity>SEATTLE</rptOwnerCity>
            <rptOwnerState>WA</rptOwnerState>
            <rptOwnerZipCode>98125</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>President &amp; CEO</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-05-21</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>11239</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.8797</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>13898</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>22254</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Ensisheim Partners, LLC</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $0.8794 to $0.9100. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of share purchased at each separate price.</footnote>
        <footnote id="F2">Ensisheim Partners, LLC (&quot;Ensisheim&quot;) is wholly owned by the Reporting Person and Dr. Shu-Chih Chen. The Reporting Person and Dr. Chen share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Steven C. Quay</signatureName>
        <signatureDate>2025-05-22</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
